Ang-1-releasing RADA16 peptide coating modulates inflammation and suppresses smooth muscle proliferation
Background
Post-stent implantation vascular complications, including impaired re-endothelialization and persistent inflammation, frequently lead to late-stage thrombosis and in-stent restenosis. Current approaches often fall short in simultaneously promoting healing and suppressing detrimental cell proliferation. Angiopoietin-1 (Ang-1) is a crucial regulatory molecule for vascular homeostasis, coordinating endothelial regeneration and vascular stabilization. Leveraging self-assembling peptides offers a promising avenue for targeted vascular therapy to address these complex issues.
Study Design
Researchers engineered a RADA16 peptide-based coating loaded with Ang-1 to mimic the unbound state of endogenous Ang-1. The study evaluated the coating's ability to modulate inflammatory responses, promote re-endothelialization, and accelerate vascular repair. They assessed sustained Ang-1 release, cytocompatibility, and effects on human umbilical vein endothelial cells (HUVECs) and smooth muscle cells (SMCs). Macrophage (MA) proliferation and pro-inflammatory cytokine secretion (IL-6, TNF-α) were also measured, alongside macrophage polarization towards the M2 phenotype.
Results
The Ang-1-loaded RADA16 coating demonstrated sustained Ang-1 release for more than 14 days, confirming its potential for prolonged therapeutic action. Both the plain peptide coating and the Ang-1-loaded version exhibited excellent cytocompatibility, indicating low toxicity.
The Ang-1 loaded coating significantly enhanced the growth and migration of human umbilical vein endothelial cells (
HUVECs) while selectively inhibiting the proliferation of smooth muscle cells (SMCs). Furthermore, the coating effectively suppressed macrophage (MA) proliferation and reduced the secretion of pro-inflammatory cytokines, specifically interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Importantly, both the plain peptide coating and the Ang-1-loaded coating promoted the polarization of macrophages toward theM2 phenotype, which is crucial for inflammation resolution and tissue repair. These findings collectively show the Ang-1-loaded coating creates an immune-favorable microenvironment conducive to vascular repair.
Key Findings
- RADA16 peptide coating enabled sustained Ang-1 release for more than 14 days.
- Ang-1 loaded coating significantly enhanced
HUVECgrowth and migration. - Ang-1 loaded coating selectively inhibited
SMCproliferation. - Coating suppressed macrophage proliferation and reduced
IL-6andTNF-αsecretion. - Both coatings promoted macrophage polarization toward the
M2 phenotype.
Why It Matters
This research offers a novel strategy to address critical post-stent complications by simultaneously promoting vascular healing and suppressing detrimental cell growth. For clinicians, an Ang-1-eluting stent coating could significantly reduce rates of in-stent restenosis and late-stage thrombosis, improving long-term patient outcomes. The ability to sustain Ang-1 release for over 14 days suggests a durable therapeutic effect, potentially reducing the need for repeat interventions. While currently an in-vitro study, this work lays the groundwork for developing next-generation stent technologies that actively modulate the immune microenvironment and accelerate vascular repair. Further preclinical animal studies are needed to validate efficacy and safety in vivo.
ang-1
rada16
self-assembling-peptide
vascular-repair
inflammation
restenosis